Title	Date

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced

27 December

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

27 December

First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company

18 December

First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders

14 December

First Wave BioPharma to Participate in BIO Partnering @JPM During “J.P. Morgan Week 2024”

06 December

First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Conference

05 December

Date and Time Announced for First Wave BioPharma CEO James Sapirstein’s Presentation at the 2023 BIO Investor Forum

10 October

First Wave BioPharma CEO James Sapirstein to Present at the 2023 Roth Healthcare Opportunities Conference

03 October

First Wave BioPharma To Present at the BIO Investor Forum

15 September

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.0 Million Gross Proceeds Priced At-the-Market

14 September

First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi

14 September

First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

05 September

First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering

19 July

First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation

13 July

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

05 July

First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

28 June

First Wave BioPharma Strengthens Intellectual Property Estate

27 June

First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference (July 28-30)

15 June

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-Market

13 June

First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis

13 June

First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference

15 May

First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

11 May

First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

25 April

First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

13 March

First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis

10 March

First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

09 March

First Wave BioPharma to Participate in ‘Fireside Chat’ at the 35th Annual Roth Conference

28 February

First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference

21 February

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

13 February

First Wave BioPharma Regains Compliance With Nasdaq’s Minimum Bid Price Requirement

07 February

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

02 February

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

31 January

First Wave BioPharma to Present at the BIO CEO & Investor Conference

30 January

First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio

25 January

First Wave BioPharma to Present at Sequire Biotechnology Conference

24 January

First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency

13 January

First Wave BioPharma Announces Results of Special Meeting of Stockholders

13 January

First Wave BioPharma Announces Adjournment of Special Meeting

09 January

Title	Date

First Wave BioPharma to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2023”

12 December

First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase

05 December

First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase

30 November

First Wave BioPharma Announces Distribution of Series F Preferred Stock to Holders of Its Common Stock

25 November

First Wave BioPharma, Inc. Announces Closing of Private Placement

22 November

First Wave BioPharma, Inc. Announces Private Placement

21 November

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

16 November

First Wave BioPharma Engages Rho to Manage Phase 2 Clinical Trial of Enhanced Adrulipase Formulation

31 October

First Wave BioPharma, Inc. Announces Closing of $6.0 Million Public Offering

11 October

First Wave BioPharma Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360

10 October

First Wave BioPharma, Inc. Announces Pricing of $6.0 Million Public Offering

06 October

First Wave BioPharma’s CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference

28 September

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

19 September

First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Fall Webconference

14 September

First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

07 September

First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract

31 August

First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022

29 August

First Wave BioPharma, Inc. Announces Reverse Stock Split

25 August

First Wave BioPharma, Inc. Announces Private Placement

15 July

First Wave BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Investment Conference

17 May

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders

29 April

First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio

27 April

First Wave BioPharma Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

28 March

First Wave BioPharma to Participate in Maxim’s 2022 Virtual Growth Conference

22 March

First Wave BioPharma to Participate in ”Fireside Chat” at the 34th Annual Roth Conference

08 March

First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference

03 March

First Wave BioPharma, Inc. Announces Closing of $9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

02 March

First Wave BioPharma Announces Appointment of Sarah Romano as Chief Financial Officer

01 March

First Wave BioPharma, Inc. Announces $9 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

28 February

First Wave BioPharma to Participate in the 2022 BIO CEO & Investor Conference

07 February

First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program

13 January

First Wave BioPharma Announces Further Adjournment of Annual Meeting

07 January

First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

06 January

First Wave BioPharma to Participate in Two Investor Conferences in January 2022

04 January

Title	Date

First Wave BioPharma Announces Adjournment of Annual Meeting

17 December

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders

13 December

First Wave BioPharma Names Brian Feagan, M.D., to Scientific Advisory Board

09 December

First Wave BioPharma’s CEO and President, James Sapirstein, to Participate in CEO Panel Discussion at 2021 BioFlorida Conference

06 December

First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections

30 November

First Wave BioPharma Announces Restructuring of Merger Consideration Payment Terms With Former Shareholders of First Wave Bio

16 November

First Wave BioPharma Forms Steering Committee for Phase 2a PASSPORT Clinical Trial to Evaluate FW-ICI-AC in Cancer Patients with Immune Checkpoint Inhibitor-Associated Colitis

21 October

First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-ICI-AC as Treatment for Immune Checkpoint Inhibitor-Associated Colitis

19 October

First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

14 October

First Wave BioPharma Announces Two Additions to Scientific Advisory Board

12 October

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

28 September

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

21 September

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

14 September

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

13 September

AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

10 September

AzurRx BioPharma Announces Reverse Stock Split

10 September

AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

09 September

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis

08 September

AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

07 September

AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)

18 August

AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819

17 August

AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

16 August

AzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

12 August

AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

10 August

AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter’s Option to Purchase Additional Shares

27 July

AzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 Million

23 July

AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock

22 July

AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital

08 June

AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

07 June

AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)

19 May

AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

13 May

AzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit)

12 May

AzurRx BioPharma to Present at Investor Summit Group’s Q2 Virtual Investor Summit (May 17)

11 May

AzurRx BioPharma to Present at the Emerging Growth Conference (May 12)

11 May

AzurRx BioPharma CEO Issues Letter to Shareholders

15 April

AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis

13 April

AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

06 April

AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call

31 March

AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

31 March

AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

22 March

AzurRx BioPharma Announces Completion of Enrollment in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

16 March

AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)

10 March

AzurRx BioPharma Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

08 March

AzurRx BioPharma to Participate in the 33rd Annual Roth Conference

08 March

AzurRx BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Life Sciences Conference

02 March

AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors

24 February

AzurRx BioPharma to Present at The Microcap Rodeo Winter Wonderland Conference

16 February

AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections

09 February

AzurRx BioPharma to Present at BIO CEO & Investor Digital Conference

08 February

AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819

28 January

AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients

26 January

AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients

21 January

AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections

12 January

AzurRx BioPharma CEO Issues Letter to Shareholders

08 January

AzurRx BioPharma to Participate in Biotech Showcase Digital 2021 Conference

07 January

AzurRx BioPharma to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference

06 January

AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event

05 January

AzurRx BioPharma Announces $8.0 Million Offerings

04 January

AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections

04 January

Title	Date

AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

30 November

AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients

17 November

AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production

10 November

AzurRx BioPharma Provides Insight into Drawbacks of Using Porcine Products in Production of Pharmaceuticals and Medicinals, Offers Update on Efforts to Produce Synthetic Alternatives

29 October

AzurRx BioPharma Announces Formation of Scientific Advisory Board

21 October

AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis

14 October

AzurRx BioPharma CEO Issues Letter to Shareholders

07 October

AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference

15 September

AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)

31 August

AzurRx BioPharma to Present at The LD 500 Virtual Conference (September 4th)

18 August

AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

17 August

AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

13 August

AzurRx BioPharma CEO Issues Clarifying Statement to Shareholders

12 August

AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

11 August

AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis – with First Patient Screened and Three Clinical Trial Sites Activated

22 July

AzurRx BioPharma Closes $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange

20 July

AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product

07 May

AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit)

05 May

AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

30 April

AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites

29 April

AzurRx BioPharma Issues Letter to Shareholders

21 April

Argus Research Initiates Equity Research Report Coverage on AzurRx BioPharma, Inc. (NasdaqCM: AZRX)

20 April

AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product

17 April

AzurRx BioPharma to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020

15 April

AzurRx Appoints Gregory Oakes to its Board of Directors

09 April

AzurRx BioPharma Receives $642,000 for its 2017 CIR (French Research Tax Credit)

01 April

AzurRx BioPharma to Present at the New York City based Investor Summit on March 25th-26th

18 March

AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit)

02 March

AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference

18 February

AzurRx BioPharma Announces Closing of $6.9 Million Private Placement

13 January

AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco

10 January

AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th)

06 January

Title	Date

AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

14 November

AzurRx BioPharma CEO Issues Letter to Shareholders

22 October

AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data

17 October

AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

15 October

AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer

10 October

AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients

25 September

AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

13 August

AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock

18 July

AzurRx BioPharma Announces Proposed Public Offering of Common Stock

18 July

AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET

09 July

AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

09 July

AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers

07 June

AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial

23 May

AzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference

21 May

AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial

23 April

Expanded MS1819-SD Global Commercialization Rights Now Owned by AzurRx BioPharma along with Full Development Rights

02 April

AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference

18 March

AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20)

15 March

AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting

12 March

AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial

20 February

Title	Date

AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients

19 December

AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group

12 December

AzurRx BioPharma to Present at Upcoming Investor Conferences

04 December

AzurRx BioPharma to Present at the 11th Annual LD Micro Main Event

29 November

AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI

01 November

AzurRx BioPharma Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

16 October

AzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic Pancreatitis

24 September

AzurRx BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference on September 5th

28 August

AzurRx BioPharma to Present at the 2018 Cannacord Genuity 38th Annual Growth Conference (August 9th)

01 August

AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency

29 June

AzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer

30 May

AzurRx BioPharma Announces Pricing of $10.4 Million Public Offering of Common Stock

01 May

AzurRx BioPharma Announces Proposed Public Offering of Common Stock

01 May

AzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic Insufficiency (EPI)

23 April

AzurRx BioPharma Announces Positive Preclinical Data with AZX1103

18 April

AzurRx BioPharma to Present at the 30th Annual ROTH Conference (March 12th)

28 February

AzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SD

12 February

AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference (February 12th)

09 February

AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD for Exocrine Pancreatic Insufficiency

18 January

AzurRx BioPharma Receives $2 Million in Proceeds from Exercise of Warrants

17 January

Title	Date

AzurRx BioPharma Announces Publication of U.S. Patent Application for AZX1101

20 December

AzurRx BioPharma to Present at the Biotech Showcase 2018 Conference (January 8th)

04 December

AzurRx BioPharma to Present at the 2017 LD Micro 10th Annual Main Event Conference (December 5th)

01 December

AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) Submission

20 October

AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors

16 October

AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)

27 September

AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer

25 September

AzurRx BioPharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 12

24 August

AzurRx Reaches 6th Patient Enrollment of Phase IIa Trial of MS1819 for Treatment of Exocrine Pancreatic Insufficiency Associated with Chronic Pancreatitis

23 August

AzurRx BioPharma Announces Closing of $5.0 Million Private Financing

08 June

AzurRx BioPharma to Present at the 2017 LD Micro Invitational Conference (June 6) and the 2017 Marcum MicroCap Conference (June 15)

06 June

AzurRx Provides Update on MS1819 Phase II Trial

12 April

AzurRx Announces Addition of Charles J Casamento to the Board of Directors

08 March

Title	Date

AzurRx BioPharma to Present at the 2017 Biotech Showcase Conference

28 December

AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Exocrine Pancreatic Insufficiency

21 December

WallachBeth Capital Initiates Research Coverage of AzurRx BioPharma

12 December

AzurRx BioPharma Announces Agreement in Principle with TransChem for MTAN Inhibition Technology

06 December

AzurRx CEO Provides Shareholders With a "State of the Union" Communication

01 December

AzurRx BioPharma to Present at the 9th Annual LD Micro Main Event

30 November

AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients

17 November

AzurRx BioPharma Inc. (Nasdaq: AZRX) to Ring The Nasdaq Stock Market Closing Bell

19 October

AzurRx BioPharma Announces Pricing of Initial Public Offering

11 October

Title	Date

AzurRx Announces Addition of Ed Borkowski to the Board of Directors

28 May

Title	Date

AzurRx Announces Issuance of U.S. Patent for its MS1819 lipase compound

31 July